Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "rare-diseases"

151 News Found

Budget 2026–27: Rs. 1,06,530.42 crore allocated to Ministry of Health and Family Welfare
Policy | February 01, 2026

Budget 2026–27: Rs. 1,06,530.42 crore allocated to Ministry of Health and Family Welfare

The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education


Biocon Biologics gets credit boost from S&P, outlook stable
News | January 30, 2026

Biocon Biologics gets credit boost from S&P, outlook stable

The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’


Metropolis Healthcare launches Genomics Centre to scale precision diagnostics and research
R&D | January 14, 2026

Metropolis Healthcare launches Genomics Centre to scale precision diagnostics and research

Backed by two CAP - accredited genomics labs in Delhi NCR and Mumbai, supporting oncology, reproductive health, neurology, transplant immunology, and rare diseases


Italfarmaco and JCR Pharmaceuticals partner to bring Duchenne therapy to Japan
News | December 30, 2025

Italfarmaco and JCR Pharmaceuticals partner to bring Duchenne therapy to Japan

The partnership also sets the stage for broader collaboration on rare disease treatments


EU nod to Wayrilz as breakthrough treatment for hard-to-treat ITP
Drug Approval | December 27, 2025

EU nod to Wayrilz as breakthrough treatment for hard-to-treat ITP

Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation


Pharma overhaul: EMA hails “Once-in-a-Generation” reform
Policy | December 16, 2025

Pharma overhaul: EMA hails “Once-in-a-Generation” reform

The reform is set to modernise how medicines are developed, authorised, and made available across the EU


Sanofi secures two breakthrough nods in China for rare blood disorders
News | December 16, 2025

Sanofi secures two breakthrough nods in China for rare blood disorders

Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia